Russia has given authorization for the single-dose Sputnik Light version of its COVID-19 vaccine for use, reported the Russian Direct Investment Fund (RDIF) on Thursday.

The one-shot vaccine has been developed by Moscows Gamaleya Institute, and the RDIF has stated that it is 79.4% effective against COVID-19 and is priced below $10 a dose. It has been designated for export and could enhance the proportion of people with partial immunity.

A Phase III clinical trial with 7,000 individuals was going on in Russia, the United Arab Emirates, Ghana and other countries, stated the RDIF, and theinterim results are expected this month.

A potential use of this vaccine is that it can be shipped to a country fighting an acute outbreak that needs to be repressed quickly… (ET Healthworld – Reuters, May 7, 2021)